Cardiol Therapeutics (TSE:CRDL) Trading Up 11.4% – Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL) shares rose 11.4% during trading on Thursday . The stock traded as high as C$1.81 and last traded at C$1.76. Approximately 138,484 shares traded hands during trading, an increase of 46% from the average session volume of 95,163 shares. The stock had previously closed at C$1.58.

Cardiol Therapeutics Stock Up 11.4%

The business’s fifty day moving average price is C$1.62 and its 200 day moving average price is C$1.57. The firm has a market capitalization of C$202.88 million, a price-to-earnings ratio of -4.51 and a beta of 0.30. The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings results on Monday, May 11th. The company reported C($0.10) earnings per share for the quarter. On average, equities analysts expect that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.